The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Stock Advisor launched in February of 2002. Moderna, Inc. develops medicines based on messenger RNA (mRNA). #MRNA.
Just enter your email address below.
"The expanded agreement will begin immediately in order to rapidly meet Moderna's increasing demand over the upcoming months, with an emphasis on securing their future long-term supply," CordenPharma said in a press release. The company could have potential blockbuster vaccine sales in 2021, he said. Joe honed his investing skills as an analyst for Stock Advisor, Supernova, and Fool One. • Is Electric Vehicle Stock Workhorse Group a Buy at $20? Shares of Moderna (ticker: MRNA) were up 16% at $21.63 on Tuesday. Most Popular Stories View All Stocktwits is the largest social network for finance. • Dangerous Outlook for Stocks Into Election, • Forget FAAMG, Buy These 4 Top Stocks Instead. Moderna, Inc. develops medicines based on messenger RNA (mRNA). Cancel. Sign Up. Copyright © 2020. Enjoy free access to the POWR Ratings for all stocks and ETFs on the quote pages.
• Is Electric Vehicle Stock Workhorse Group a Buy at $20? Cancel. Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. NASDAQ: MRNA $72.72 up $1.76 (2.48%) Related Articles.
You may wish to incorporate that into your trading strategies. Trade Grade Sign Up to See Ratings...FREE! POWR Components: Trade Grade Buy & Hold Grade Peer Grade Industry Rank.
Image source: Getty Images.
GET POWR RATINGS... FREE!
After its phase 1 clinical study demonstrated promising early results for its experimental mRNA-1273 drug, Moderna is now expected to begin a phase 2 trial.
Moderna Completes Enrollment in Its Late-Stage Coronavirus Vaccine Trial, US faces major hurdles for COVID-19 vaccine distribution: Vaccine advisory committee, Moderna Hits Enrollment Target In Late-Stage Coronavirus Vaccine Study, Moderna Inc. stock rises Thursday, outperforms market, Moderna Expects COVID-19 Vaccine Data in November: ETFs to Gain, Epidemiologist on Moderna’s COVID-19 vaccine: ‘It’s promising’, FDA Covid Meeting Shows the Companies Behind the Vaccines, Pfizer, Moderna Vaccines, Gilead Treatment In Focus As Health Firms Report Q3 Earnings, Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline, Even More (Almost) Real-Time Stock Alerts. Rooms Rankings Earnings Calendar Shop. • Aurora Cannabis vs. Canopy Growth: Which Stock is a Better Buy. Moderna stock rose on Thursday after it struck a deal to ramp up its COVID-19 vaccine production capabilities. If approved, RNA-1273 could be a $10-billion-a-year drug, said Piper Sandler's Tenthoff, according to Bloomberg. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Get the latest Moderna, Inc. (MRNA) stock news and headlines to help you in your trading and investing decisions. Rooms Rankings Earnings Calendar Shop.
Real-time trade and investing ideas on Moderna, Inc. MRNA from the largest community of traders and investors.
Log In.
"We are hopeful Moderna's technology represents a positive impact for people suffering from COVID-19 across the globe, and we are honored to contribute to the industry as a whole," CordenPharma CEO Dr. Michael Quirmbach said. See you at the top! Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. How Profitable Is Coronavirus Vaccine Development? Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
in Biotech. Market data powered by FactSet and Web Financial Group. Industry Rank, Ranked of 384 • Dangerous Outlook for Stocks Into Election, • Forget FAAMG, Buy These 4 Top Stocks Instead. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life.
To see all exchange delays and terms of use, please see disclaimer. Peer Grade Peer Grade
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Let's conquer your financial goals together...faster. S&P 500 0.00%. Get these alerts pushed to you via our Recent Intraday Alerts -- Read the latest StockTalks, investment ideas, and community discussion on Moderna, Inc. (MRNA). Industry Rank: Ranked of 372 in Biotech.